Holen Sie sich die Stockscreener-App
0.9301
0.11%
-0.001
Schlusskurs vom Vortag:
$0.9311
Offen:
$0.92
24-Stunden-Volumen:
240.77K
Relative Volume:
0.58
Marktkapitalisierung:
$37.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.58M
KGV:
-0.351
EPS:
-2.65
Netto-Cashflow:
$-42.82M
1W Leistung:
-5.67%
1M Leistung:
-33.09%
6M Leistung:
-48.61%
1J Leistung:
-33.09%
1-Tages-Spanne:
$0.91
$0.937
1-Wochen-Bereich:
$0.8901
$1.03
52-Wochen-Spanne:
$0.808
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Firmenname
Iterum Therapeutics Plc
Sektor
Branche
Telefon
(872) 225-6077
Adresse
3 DUBLIN LANDINGS, DUBLIN 1
Vergleichen Sie ITRM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.93 | 37.14M | 0 | -35.58M | -42.82M | -2.65 |
|
ONC
Beigene Ltd Adr
|
241.88 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.02 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.82 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.93 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2021-03-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | Herabstufung | Gabelli & Co | Buy → Sell |
| 2019-12-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Iterum Therapeutics Plc Aktie (ITRM) Neueste Nachrichten
Pfizer grants Iterum payment extension for FDA-approved antibiotic By Investing.com - Investing.com South Africa
Pfizer grants Iterum payment extension for FDA-approved antibiotic - Investing.com Australia
Iterum Therapeutics (ITRM) Extends $20M Payment Deadline with Pf - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory No - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory Note - The Manila Times
Iterum Therapeutics Announces Extension of $20 Million Regulatory Milestone Payment Deadline with Pfizer to 2029 - Nasdaq
Iterum Gains 3-Year Extension on $20M Pfizer Payment, Strengthens ORLYNVAH Launch Strategy - Stock Titan
Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026 - MSN
When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable? - simplywall.st
Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2025 Earnings Call Transcript - Insider Monkey
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Finance
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: - GuruFocus
ITRM Plans Fourth-Quarter Launch for ORLYNVAH in UTI Treatment | - GuruFocus
Iterum Therapeutics (ITRM) Projects Adequate Funding Until 2026 - GuruFocus
Iterum Therapeutics plc SEC 10-Q Report - TradingView
Iterum Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
Transcript : Iterum Therapeutics plc, Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Q1 Earnings Estimate for ITRM Issued By HC Wainwright - Defense World
Iterum Therapeutics’ (ITRM) Buy Rating Reiterated at HC Wainwright - Defense World
Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven? - Yahoo Finance
Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Monday - Defense World
Iterum Therapeutics (ITRM) Receives Buy Rating from HC Wainwrigh - GuruFocus
Iterum Therapeutics (ITRM) Receives Buy Rating from Analyst | IT - GuruFocus
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 - Yahoo Finance
Renaissance Technologies LLC Purchases Shares of 438,816 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Check Out Iterum Therapeutics Plc (ITRM)’s Trade Data Rather Than the Analysts’ Views - Sete News
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares - The Manila Times
Iterum Therapeutics Raises $5M from Single Investor: Major Push for Antibiotic Commercialization - Stock Titan
Iterum Therapeutics Plc: Rising -64.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Iterum Therapeutics Plc (ITRM) Becoming More Attractive for Investors - knoxdaily.com
Iterum Therapeutics (ITRM) Secures $5 Million in Direct Offering - GuruFocus
Evaluating ITRM’s financial ratios for a profitable investment - uspostnews.com
Iterum Therapeutics secures $5 million in direct offering - Investing.com
Iterum Therapeutics Announces $5 Million Registered Direct Offering Of Ordinary Shares - marketscreener.com
Iterum Therapeutics plc Announces Definitive Agreement for $5 Million Registered Direct Offering of Shares - Nasdaq
Iterum Therapeutics Secures Critical $5M Funding: ORLYNVAH Drug Launch Plans Accelerate - Stock Titan
ITRM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Iterum Therapeutics Plc (NASDAQ:ITRM) Shares Surged 24.11% In A Week – But Can It Maintain Its Gains? - Marketing Sentinel
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics - The Manila Times
Groundbreaking Research Reveals Age-Specific Patterns in Antibiotic Resistance for UTI Patients - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
What is Iterum Therapeutics Plc (ITRM) Stock Return on Shareholders’ Capital? - Sete News
Iterum Therapeutics Plc (ITRM): Significant Improvements, Worth Considering - stocksregister.com
Sulopenem Etzadroxil/Probenecid (orlynvah) by Iterum - openPR.com
Iterum outlines ORLYNVAH's market potential with exclusivity through 2034 - MSN
Iterum Therapeutics appoints Joseph Whalen to its Board By Investing.com - Investing.com Canada
Iterum Therapeutics appoints Joseph Whalen to its Board - Investing.com
Iterum Therapeutics Appoints New Board Members - TipRanks
Sanctuary Advisors LLC Invests $35,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Down 5.3% in January - Defense World
Finanzdaten der Iterum Therapeutics Plc-Aktie (ITRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
17.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):